» Articles » PMID: 35982541

Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV

Abstract

Background: HIV-associated neurocognitive disorders (HAND) have been suggested as persistent even with effective antiretroviral therapy (ART). Aims were to evaluate HAND prevalence and associated factors, in a large cohort of people-with-HIV (PWH).

Methods: ART-treated PWH, underwent a neuropsychological examination through a battery of 12 tests exploring 5 different domains, between 2009 and 2020, were included in this cross-sectional analysis. HAND were classified according to Frascati's criteria. Participants were defined as complaining or not-complaining if a cognitive complaint was reported or not. Chi-square for trend and multivariable logistic regression were fitted.

Results: Overall, 1424 PWH were enrolled during four three-years periods. HAND prevalence was 24%; among complainers (572/1424), it was 38%, higher than among not-complainers (15%). Over the study period, a decreasing HAND prevalence was found in the entire population (P < 0.001) and in complaining (P < 0.001); in not-complaining it remained stable (P = 0.182). Factors associated with HAND were older age, lower educational level, lower current CD4+ T-cell count and HCV co-infection. Compared to nonnucleoside reverse transcriptase inhibitors, receiving dual and integrase strand transfer inhibitor (INSTI)-based therapies was associated with a decreased risk of HAND, as well as being tested in more recent years.

Conclusions: In this large cohort of ART-treated PWH, mostly virologically suppressed, a remarkable decreasing HAND prevalence was observed. Besides HIV- and patient-related factors, the reduced risk of HAND found with dual and INSTI-based regimens along with a more recent ART initiation, could suggest a potential role of new treatment strategies in this decline, due to their greater virologic efficacy and better tolerability.

Citing Articles

Altered angular gyrus activation during the digit symbol substitution test in people living with HIV: beyond information processing speed deficits.

Cai D, Song P, Song F, Shi Y Sci Rep. 2025; 15(1):5808.

PMID: 39962187 PMC: 11833122. DOI: 10.1038/s41598-025-89388-0.


Risk factors for cognitive decline in persons with HIV.

Henderson M, Winston A Curr Opin Infect Dis. 2024; 38(1):37-43.

PMID: 39641182 PMC: 11676619. DOI: 10.1097/QCO.0000000000001080.


HIV transcription persists in the brain of virally suppressed people with HIV.

Jamal Eddine J, Angelovich T, Zhou J, Byrnes S, Tumpach C, Saraya N PLoS Pathog. 2024; 20(8):e1012446.

PMID: 39116185 PMC: 11335163. DOI: 10.1371/journal.ppat.1012446.


Limited HIV-associated neuropathologies and lack of immune activation in sub-saharan African individuals with late-stage subtype C HIV-1 infection.

Liu Z, Julius P, Mudenda V, Kang G, Del Valle L, West J J Neurovirol. 2024; 30(3):303-315.

PMID: 38943022 DOI: 10.1007/s13365-024-01219-6.


Neurocognitive profile in HIV subjects on INSTI-regimen- one year follow up: Is there room for optimism?.

Brkic-Jovanovic N, Karaman M, Andric V, Maric D, Brkic S, Bugarski-Ignjatovic V PLoS One. 2024; 19(6):e0306278.

PMID: 38923982 PMC: 11207154. DOI: 10.1371/journal.pone.0306278.


References
1.
Ciccarelli N . Considerations on nosology for HIV-associated neurocognitive disorders: it is time to update?. Infection. 2019; 48(1):37-42. DOI: 10.1007/s15010-019-01373-8. View

2.
Maki P, Rubin L, Valcour V, Martin E, Crystal H, Young M . Cognitive function in women with HIV: findings from the Women's Interagency HIV Study. Neurology. 2014; 84(3):231-40. PMC: 4335997. DOI: 10.1212/WNL.0000000000001151. View

3.
Sacktor N . Changing clinical phenotypes of HIV-associated neurocognitive disorders. J Neurovirol. 2017; 24(2):141-145. PMC: 5787044. DOI: 10.1007/s13365-017-0556-6. View

4.
Gisslen M, Price R, Nilsson S . The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis. 2011; 11:356. PMC: 3260107. DOI: 10.1186/1471-2334-11-356. View

5.
Simioni S, Cavassini M, Annoni J, Rimbault Abraham A, Bourquin I, Schiffer V . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2009; 24(9):1243-50. DOI: 10.1097/QAD.0b013e3283354a7b. View